These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 26697509)

  • 21. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.
    Kobayashi M; Suzuki F; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2017 Mar; 89(3):476-483. PubMed ID: 27531586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
    Mira JA; García-Rey S; Rivero A; de los Santos-Gil I; López-Cortés LF; Girón-González JA; Téllez F; Márquez M; Merino D; Ríos-Villegas MJ; Macías J; Rivero-Juárez A; Pineda JA
    Clin Infect Dis; 2012 Dec; 55(12):1719-26. PubMed ID: 22955435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.
    Neukam K; Barreiro P; Rivero-Juárez A; Caruz A; Mira JA; Camacho A; Macías J; Rivero A; Soriano V; Pineda JA
    J Infect; 2013 Jul; 67(1):59-64. PubMed ID: 23542783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of antiviral therapy for HCV on lipid levels.
    Mauss S; Berger F; Wehmeyer MH; Ingiliz P; Hueppe D; Lutz T; Simon KG; Schewe K; Rockstroh JK; Baumgarten A; Christensen S
    Antivir Ther; 2017; 21(1):81-88. PubMed ID: 27685337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of TRIM22 mRNA in chronic hepatitis C patients treated with direct-acting antiviral drugs.
    Naveed M; Ali A; Sheikh N; Rafique S; Idrees M
    APMIS; 2020 Apr; 128(4):326-334. PubMed ID: 31863490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
    Mira JA; Rivero-Juárez A; López-Cortés LF; Girón-González JA; Téllez F; de los Santos-Gil I; Macías J; Merino D; Márquez M; Ríos-Villegas MJ; Gea I; Merchante N; Rivero A; Torres-Cornejo A; Pineda JA;
    Clin Infect Dis; 2013 Jun; 56(11):1646-53. PubMed ID: 23429381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
    Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
    BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C: Treatment of difficult to treat patients.
    Hilgenfeldt EG; Schlachterman A; Firpi RJ
    World J Hepatol; 2015 Jul; 7(15):1953-63. PubMed ID: 26244069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
    Chayama K; Takahashi S; Toyota J; Karino Y; Ikeda K; Ishikawa H; Watanabe H; McPhee F; Hughes E; Kumada H
    Hepatology; 2012 Mar; 55(3):742-8. PubMed ID: 21987462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV-coinfected patients with mixed cryoglobulinaemia.
    Miailhes P; Hartig-Lavie K; Virlogeux V; Pradat P; Diakite M; Uhres AC; Zoulim F; Sarda MN
    Clin Microbiol Infect; 2018 Nov; 24(11):1215.e1-1215.e4. PubMed ID: 29870852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
    J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy.
    Virlogeux V; Berthillon P; Bordes I; Larrat S; Crouy S; Scholtès C; Pradat P; Maynard M; Zoulim F; Leroy V; Chemin I; Trépo C; Petit MA
    Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):313-318. PubMed ID: 29551607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Profile and Response to Treatment with Pegylated Interferon α 2b and Ribavirin in Chronic Hepatitis C-A Reappraisal from a Tertiary Care Center in Northern India.
    Dixit VK; Ghosh JK; Lamtha SC; Kaushik P; Goyal SK; Behera MK; Singh N; Jain AK
    J Clin Exp Hepatol; 2014 Jun; 4(2):101-5. PubMed ID: 25755547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis.
    Yee BE; Nguyen NH; Zhang B; Lin D; Vutien P; Wong CR; Lutchman GA; Nguyen MH
    BMJ Open Gastroenterol; 2015; 2(1):e000049. PubMed ID: 26462288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoantibodies against "rods and rings"-related IMPDH2 in hepatitis C genotype 1 and DAA therapy in a "real life" cohort.
    Dammermann W; Polywka S; Dettmann I; Mindorf S; Komorowski L; Wehmeyer M; Schulze Zur Wiesch J; Stöcker W; Lüth S
    Med Microbiol Immunol; 2017 Oct; 206(5):379-382. PubMed ID: 28815296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy.
    Sandoughdaran S; Alavian SM; Sharafi H; Behnava B; Salimi S; Mehrnoush L; Karimi Elizee P; Keshvari M
    Hepat Mon; 2015 Jan; 15(1):e23564. PubMed ID: 25741371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy.
    Sugimoto K; Kim SR; El-Shamy A; Imoto S; Fujioka H; Kim KI; Tanaka Y; Yano Y; Kim SK; Hasegawa Y; Fujinami A; Ohta M; Hatae T; Hotta H; Hayashi Y; Kudo M
    Dig Dis; 2013; 31(5-6):434-9. PubMed ID: 24281017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the Hepatitis C Continua of Care Between Hepatitis C Virus/HIV Coinfected and Hepatitis C Virus Mono-Infected Patients in Two Treatment Eras During 2008-2015.
    Roberson JL; Lagasca AM; Kan VL
    AIDS Res Hum Retroviruses; 2018 Feb; 34(2):148-155. PubMed ID: 28974107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Re-treatment of chronic HCV infection in HIV co-infected patients and predictors of sustained viral response.
    Krastinova E; Bani-Sadr F; Fromentin D; Goujard C; Hessamfar M; Yazdanpanah Y; Pol S; Cacoub P; Perronne C; Carrat F
    J Infect; 2014 May; 68(5):462-6. PubMed ID: 24378283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term efficacy of Peg-Interferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infection.
    Yeh ML; Hsieh MY; Huang CI; Huang CF; Hsieh MH; Huang JF; Dai CY; Chuang WL; Yu ML
    J Gastroenterol Hepatol; 2016 Apr; 31(4):835-41. PubMed ID: 26478984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.